Biohit Oyj

Regulatory Filings • Nov 18, 2013

Biohit acquires rights to H. pylori quick test – new superior test to product range during Q4

Biohit acquires rights to H. pylori quick test – new superior test to product range during Q4

Biohit Oyj Stock Exchange Release November 18, 2013 at 11:45 a.m. local time
(EET)

Biohit Oyj acquires the rights to the UFT300 test, which is a rapid test for
the diagnosis of Helicobacter pylori infection. Along with the agreement, the
Italian developer, Advanced Biomedical Systems s.r.l. (ABS) gives Biohit the
patent and distribution rights for the test. The purchase price is EUR 350,000
and the new H. pylori quick test will be incorporated into Biohit's product
range during the fourth quarter, 2013.

UFT300 is the only test available on the market which permits the reading of
the result as well as confirmation within 5 minutes from the sample insertion;
UFT300 combines the superior performance characteristics (sensitivity 94,5%,
specificity 100%, accuracy 97,5%) with the maximum speed if compared with all
the competitors' tests commercially available worldwide (1). After a transition
period, the rights to the earlier version of the test (UFT200) will also be
transferred to Biohit.

CEO Semi Korpela, Biohit Oyj: "This is bad news for helicobacter. Our test is
superior.”

Source (1): Vaira D et al 2010 Accuracy of a new ultrafast rapid urease test to
diagnose Helicobacter pylori infection in 1000 consecutive dyspeptic patients

Attachment: UFT300 Urea Ultra-Fast test for diagnosing H. pylori infection

Additional information:

CEO Semi Korpela, Biohit Oyj
Tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company established in
1988. Biohit's mission is "Innovating for Health". The purpose of the company
is to take social responsibility and produce innovation, new technologies and
analysis systems for use in medicine, research institutions and industry,
helping to promote research and diagnostics and to improve the quality of life
of people by means of preventing disease, human suffering and financial loss.
We are committed to social responsibility and it is our duty to spread
knowledge about the Group I human carcinogen, acetaldehyde, and innovate and
develop the marketing and availability of our products and services. Biohit is
headquartered in Helsinki, Finland and its subsidiaries are located in China,
Italy and the United Kingdom. Since 1999, Biohit's Series B shares (BIOBV) have
been listed in the NASDAQ OMX Helsinki Oy Small cap/Healthcare sector.
www.biohithealthcare.com

Attachments: